Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M951Revenue $M113Net Margin (%)-36.9Altman Z-Score1.8
Enterprise Value $M877EPS $-0.3Operating Margin %-32.5Piotroski F-Score5
P/E(ttm)--Beneish M-Score-2.6Pre-tax Margin (%)-36.9Higher ROA y-yY
Price/Book29.710-y EBITDA Growth Rate %7.3Quick Ratio3.2Cash flow > EarningsY
Price/Sales8.35-y EBITDA Growth Rate %0.7Current Ratio3.4Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-25.4Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-104.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M128ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with HALO

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
HALOFirst Eagle Investment 2015-09-30 Reduce-0.01%$13.25 - $24.75
($20.12)
$ 7.43-63%Reduce -2.49%4,058,500
HALOJoel Greenblatt 2015-09-30 Reduce$13.25 - $24.75
($20.12)
$ 7.43-63%Reduce -21.11%28,955
HALOKen Fisher 2015-09-30 Reduce$13.25 - $24.75
($20.12)
$ 7.43-63%Reduce -4.48%707,780
HALOFirst Eagle Investment 2015-06-30 Add0.02%$14.28 - $22.58
($17.52)
$ 7.43-58%Add 8.55%4,162,000
HALOJoel Greenblatt 2015-06-30 Buy 0.01%$14.28 - $22.58
($17.52)
$ 7.43-58%New holding36,701
HALOKen Fisher 2015-06-30 Reduce$14.28 - $22.58
($17.52)
$ 7.43-58%Reduce -2.86%740,955
HALOFirst Eagle Investment 2015-03-31 Reduce$9.82 - $16.2
($14.42)
$ 7.43-48%Reduce -3.92%3,834,050
HALOFirst Eagle Investment 2014-09-30 Add0.02%$8.67 - $10.2
($9.52)
$ 7.43-22%Add 30.25%3,640,480
HALOFirst Eagle Investment 2014-06-30 Add0.03%$7.09 - $12.31
($8.46)
$ 7.43-12%Add 94.94%2,795,080
HALOKen Fisher 2014-06-30 Buy 0.02%$7.09 - $12.31
($8.46)
$ 7.43-12%New holding791,760
HALOFirst Eagle Investment 2013-12-31 Buy 0.05%$9.66 - $15.7
($12.86)
$ 7.43-42%New holding1,294,580
HALOGeorge Soros 2011-12-31 Sold Out -0.0018%$5.72 - $9.73
($8.21)
$ 7.43-10%Sold Out0
HALOGeorge Soros 2011-09-30 Buy $5.62 - $7.29
($6.61)
$ 7.4312%New holding17,100
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

HALO is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


HALO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Stelzer LaurieCFO 2015-08-20Buy10,000$17.24-56.9view
Stelzer LaurieCFO 2015-08-20Buy10,000$17.24-56.9view
Kelley Kenneth JDirector 2015-06-18Sell20,000$21-64.62view
Kelley Kenneth JDirector 2015-03-05Sell40,000$15.33-51.53view
RAMSAY DAVID AVP and CFO 2014-09-16Buy25,000$8.9-16.52view
Torley HelenPresident and CEO 2014-09-16Buy50,000$8.92-16.7view
PATTON JOHN STUARTDirector 2014-08-19Sell75,000$9.96-25.4view
Engler RobertDirector 2014-08-14Sell35,000$9.96-25.4view
Engler RobertDirector 2014-05-15Sell126,700$7.56-1.72view
PATTON JOHN STUARTDirector 2013-09-16Sell75,000$9.13-18.62view

Quarterly/Annual Reports about HALO:

News about HALO:

Articles On GuruFocus.com
First Eagle Overseas Fund Q2 Commentary Aug 03 2015 
Insider Buys at Halozyme Look to Improve Stock Outlook Sep 18 2014 
Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Aug 06 2010 
Halozyme Therapeutics Inc. Reports Operating Results (10-Q) May 07 2010 
Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Nov 06 2009 
Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Aug 07 2009 

More From Other Websites
How to Beat the Market with Biotech -- Bluebird bio, Halozyme Therapeutics, Merrimack Pharma, and... Feb 11 2016
Halozyme To Host Fourth Quarter And 2015 Year-End Financial Results Conference Call Feb 01 2016
Halozyme To Host Fourth Quarter And 2015 Year-End Financial Results Conference Call Feb 01 2016
Halozyme Announces Closing Of $150 Million Royalty-Backed Debt Financing Jan 26 2016
HALOZYME THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 26 2016
Halozyme Announces Closing Of $150 Million Royalty-Backed Debt Financing Jan 26 2016
Halozyme Gets $5M as AbbVie Begins Dosing in Humira Trial Jan 22 2016
Halozyme Confirms $5 Million Milestone Payment From AbbVie Jan 21 2016
5 Stocks Under $10 Set to Soar Jan 21 2016
Halozyme Announces First Clinical Dosing Of Adalimumab (Humira) Using ENHANZE™ Technology Jan 21 2016
Halozyme Therapeutics (HALO) in Focus: Stock Rises 6.7% Jan 21 2016
Halozyme Announces First Clinical Dosing Of Adalimumab (Humira) Using ENHANZE™ Technology Jan 21 2016
4 Top BioPharma Movers of the Past Week Jan 16 2016
Small Companies, Big Declines: Why These Stocks Tumbled Today Jan 13 2016
HALOZYME THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 13 2016
Halozyme Therapeutics (HALO) in Focus: Stock Tumbles 16.7% Jan 12 2016
The News that Prompted Furious Trading in These 4 Stocks Today Jan 11 2016
Halozyme Therapeutics Sinks on Business Update Jan 11 2016
Halozyme Provides Key Program Updates, 2016 Financial Guidance At 34th Annual JP Morgan Healthcare... Jan 11 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK